Dermata Therapeutics (NASDAQ:DRMAW – Get Free Report) is projected to release its results before the market opens on Tuesday, August 18th. Analysts expect Dermata Therapeutics to post earnings of ($0.55) per share for the quarter.
Dermata Therapeutics Price Performance
NASDAQ DRMAW opened at $0.01 on Tuesday. The firm has a 50-day moving average price of $0.01 and a two-hundred day moving average price of $0.01. Dermata Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.03.
Dermata Therapeutics Company Profile
Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for inflammatory skin diseases. The company leverages small-molecule approaches to modulate key immune and cellular pathways in dermatologic conditions that currently lack effective or safe long-term treatments. Headquartered in Cambridge, Massachusetts, Dermata is advancing novel programs designed to address both common and severe skin disorders.
The company’s lead pipeline includes a selective topical PI3Kδ inhibitor being evaluated for the treatment of atopic dermatitis, where dysregulated immune signaling drives chronic inflammation and barrier dysfunction.
Featured Stories
- Five stocks we like better than Dermata Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
